scholarly journals Irreversible extreme freezing of gait after dopamine agonist withdrawal

2021 ◽  
Vol 9 (8) ◽  
Author(s):  
Mehri Salari ◽  
Anthony E. Lang ◽  
Leila Dargahi ◽  
Amir Hasan Habibi ◽  
Masoud Etemadifar
Keyword(s):  
Dopamine Agonist ◽  
Freezing Of Gait

The effect of bromocriptine on mammary-gland ultrastructure of hyperprolactinemic rats

1984 ◽  
Vol 42 ◽  
pp. 204-205
Author(s):  
I.C. Murray
Keyword(s):  
Mammary Gland ◽  
Dopamine Agonist ◽  
Alveolar Epithelium ◽  
Mammary Glands ◽  
Female Rats ◽  
Control Group ◽  
Cell Hyperplasia ◽  
Once Daily ◽  
Long Evans

In women, hyperprolactinemia is often due to a prolactin (PRL)-secreting adenoma or PRL cell hyperplasia. RRL excess stimulates the mammary glands and causes proliferation of the alveolar epithelium. Bromocriptine, a dopamine agonist, inhibits PRL secretion and is given to women to treat nonpuerperal galactorrhea. Old female rats have been reported to have PRL cell hyperplasia or adenoma leading to PRL hypersecretion and breast stimulation. Herein, we describe the effect of bromocriptine and consequently the reduction in serum PRL levels on the ultrastructure of rat mammary glands.Female Long-Evans rats, 23 months of age, were divided into control and bromocriptine-treated groups. The control animals were injected subcutaneously once daily with a 10% ethanol vehicle and were later divided into a normoprolactinemic control group with serum PRL levels under 30 ng/ml and a hyperprolactinemic control group with serum PRL levels above 30 ng/ml.

Dopamine agonist modeling of schizophrenia increases ethanol intake in rats

2012 ◽  
Author(s):  
A. Y. Egorov ◽  
E. O. Kutcher ◽  
N. A. Chernikova ◽  
E. V. Filatova
Keyword(s):  
Dopamine Agonist ◽  
Ethanol Intake

High dose dopamine agonist treatment and combination of dopamine agonists

2005 ◽  
Vol 32 (06) ◽  
Author(s):  
P Odin ◽  
C Oehlwein ◽  
A Storch ◽  
U Polzer ◽  
G Werner ◽  
...  
Keyword(s):  
Dopamine Agonist ◽  
Dopamine Agonists ◽  
High Dose

A case of dopamine agonist resistant macroprolactinoma

2017 ◽  
Author(s):  
Shang Shaho ◽  
William Martin Drake
Keyword(s):  
Dopamine Agonist

Update Treatment for Prolactinoma

2018 ◽  
Vol 3 (06) ◽  
Author(s):  
Chávez Hernández María Margarita ◽  
Jiménez Báez María Valeria ◽  
Armijo Medina María Fernanda ◽  
Domínguez Leyva Jorge Miguel ◽  
Góngora Valencia Karen Alejandra ◽  
...  
Keyword(s):  
Dopamine Agonist ◽  
Safety Profile ◽  
Pituitary Tumor ◽  
Common Type ◽  
Treatment Modalities ◽  
First Line ◽  
Agonist Therapy ◽  
Dopamine Agonist Therapy ◽  
Gonadal Dysfunction

Prolactinomas are the most common type of functional pituitary tumor. The present manuscript is an update on the treatment modalities for prolactinomas. Effective hyperprolactinemia treatment is of great importance, due to its potential deleterious effects including infertility, gonadal dysfunction and osteoporosis. Dopamine agonist therapy is the first line of treatment for prolactinomas; recurrence of disease after cessation of the drug may occur in patients. Its safety profile remains high, allowing its use during pregnancy.

Sign in / Sign up

Export Citation Format

Share Document